9 new craft beer taprooms in eastern Massachusetts to try this summer
Several new taprooms featuring local craft beer have opened in recent months. So if youre traveling this summer, consider visiting one or a few.
Source: wickedlocal.com
📰 Single Dose News
Page 6 - Single Dose News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Single Dose. Real-time updates on events, politics, business and more.
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Press Release
– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demo
Source: wiredprnews.com
Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be
Source: finanznachrichten.de
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With
– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure –– Safety profile generally consistent with myeloablative conditioning and autologous stem cell...
Source: pharmiweb.com
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCa...
- A Single Dose of SLS-004 Produced 19% Downregulation of mRNA and ~40% Reduction of Alpha-Synuclein Compared to the Control Group- These Results ...
New York United States Mike Moyer Anthony Marciano Exchange Commission Prnewswire Seelos Therapeutics Inc
Source: businessinsider.com
Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial
Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo, with treatment with ...
Source: pharmiweb.com
Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001 at the 2022 Annual European Hematology Association (EHA) Congress
- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR
Source: finanznachrichten.de
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022
 - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation –BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-...
Source: pharmiweb.com
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations | Antibodies
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Source: pipelinereview.com
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six month follow-up analysis, compared to ...
United States United Kingdom Great Britain Myronj Levin Company On Twitter Vanderbilt University Medical Center
Source: pharmiweb.com